CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy.
Fiche publication
Date publication
avril 2024
Journal
Cancer gene therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GODET Yann, Dr GALAINE Jeanne, Dr LOYON Romain
Tous les auteurs :
De Castro V, Galaine J, Loyon R, Godet Y
Lien Pubmed
Résumé
While CAR-T and tgTCR-T therapies have exhibited noteworthy and promising outcomes in hematologic and solid tumors respectively, a set of distinct challenges remains. Consequently, the quest for novel strategies has become imperative to safeguard and more effectively release the full functions of engineered T cells. These factors are intricately linked to the success of adoptive cell therapy. Recently, CRISPR-based technologies have emerged as a major breakthrough for maintaining T cell functions. These technologies have allowed the discovery of T cells' negative regulators such as specific cell-surface receptors, cell-signaling proteins, and transcription factors that are involved in the development or maintenance of T cell dysfunction. By employing a CRISPR-genic invalidation approach to target these negative regulators, it has become possible to prevent the emergence of hypofunctional T cells. This review revisits the establishment of the dysfunctional profile of T cells before delving into a comprehensive summary of recent CRISPR-gene invalidations, with each invalidation contributing to the enhancement of engineered T cells' antitumor capacities. The narrative unfolds as we explore how these advancements were discovered and identified, marking a significant advancement in the pursuit of superior adoptive cell therapy.
Référence
Cancer Gene Ther. 2024 04 12;: